Our Pricing

Searching for wegovy injections uk discount code options? Cured Pharmacy offers genuine UK-licensed Wegovy (semaglutide) from £79.00 with 10% off your first order using code WEIGHTLOSSNEW. Our UK-registered clinical team provides free online consultations, transparent upfront pricing, and discreet next-day delivery across the UK.

How Wegovy Injections Work for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the natural hormone GLP-1, which regulates appetite and food intake by acting on areas of the brain that control hunger.

In the landmark STEP 1 clinical trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. The medication works by slowing gastric emptying, reducing appetite, and increasing feelings of fullness after meals, helping patients adhere to reduced-calorie diets more effectively.

Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled pen. The dose is gradually increased over 16 to 20 weeks to minimise gastrointestinal side effects, starting at 0.25mg weekly and titrating up to the maintenance dose of 2.4mg weekly [2].

Wegovy Price UK: Transparent Costs at Cured Pharmacy

At Cured Pharmacy, Wegovy injections start from £79.00 per pen, with an additional 10% discount available using code WEIGHTLOSSNEW on your first order. Unlike many online pharmacies, we display transparent upfront pricing before you complete your clinical assessment, so there are no hidden costs or surprises.

Your final cost depends on your prescribed dose, which your UK prescriber determines during your free online consultation. The treatment typically involves a dose escalation schedule over several months, and our clinical team will provide clear guidance on the total programme cost during your assessment.

All Wegovy prescriptions at Cured Pharmacy include free consultation with a UK-registered prescriber, discreet packaging, and tracked delivery. We guarantee the lowest prices in the UK for genuine, MHRA-licensed medications dispensed by our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

What's Included in Your Wegovy Treatment

Every Wegovy prescription from Cured Pharmacy includes a comprehensive treatment package: free online clinical assessment completed in under three minutes, genuine UK-licensed Wegovy pens, discreet next-day delivery with tracking, ongoing prescriber support, and transparent pricing with no hidden consultation fees. Your medication arrives in 100% discreet packaging with no external branding or pharmacy labels.

Wegovy vs Mounjaro: Comparing Weight Loss Injections UK

Both Wegovy and Mounjaro are injectable medications licensed in the UK for weight management, but they work through different mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist, while Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist available in the UK [3].

Head-to-head clinical trials suggest tirzepatide may produce greater weight loss than semaglutide. In the SURPASS-2 trial, participants on the highest tirzepatide dose (15mg) achieved an average 15.7% body weight reduction compared to 5.7% with semaglutide 1mg over 40 weeks [3]. However, Wegovy uses a higher semaglutide dose (2.4mg) than the comparator in that trial.

The choice between Wegovy and Mounjaro depends on individual factors including medical history, previous treatment response, side effect tolerance, and cost considerations. Both medications require once-weekly injections and gradual dose escalation. Your UK prescriber will assess which treatment is most appropriate during your clinical consultation.

Which Treatment Is Right for You?

Your suitability for Wegovy or alternative weight loss treatments depends on several clinical factors including your BMI, existing health conditions, current medications, and previous weight loss attempts. During your free online assessment, our UK prescribers evaluate your medical history and weight loss goals to recommend the most appropriate treatment. Some patients may benefit from starting with Saxenda (daily injections) or oral medications like Orlistat, while others are suitable candidates for once-weekly options like Wegovy or Mounjaro.

Clinical Evidence: Wegovy STEP Trials Results

The efficacy and safety of Wegovy have been established through the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme, which enrolled over 4,500 participants across multiple studies [1][4]. These randomised, double-blind, placebo-controlled trials demonstrated consistent and clinically significant weight loss across diverse patient populations.

In STEP 1, 68 weeks of treatment with Wegovy 2.4mg resulted in an average weight loss of 14.9% from baseline, with 86.4% of participants achieving at least 5% weight loss and 69.1% achieving at least 10% weight loss [1]. Participants also experienced improvements in cardiometabolic risk factors including waist circumference, blood pressure, lipid profiles, and glycaemic control.

The STEP 2 trial specifically evaluated Wegovy in adults with type 2 diabetes, demonstrating an average weight reduction of 9.6% compared to 3.4% with placebo over 68 weeks, alongside improvements in HbA1c levels [4]. Long-term data from STEP 5 showed sustained weight loss of 15.2% over 104 weeks, indicating durability of effect with continued treatment [4].

How to Use Wegovy Injections: Dosing and Administration

Wegovy is administered as a subcutaneous injection once weekly, on the same day each week, at any time of day with or without meals [2]. The pre-filled pen is designed for self-administration and can be injected into the abdomen, thigh, or upper arm. Your first prescription will include detailed instructions and our clinical team can provide guidance on proper injection technique.

Treatment begins with a 0.25mg weekly dose for the first four weeks, then increases every four weeks through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly [2]. This gradual escalation helps minimise gastrointestinal side effects such as nausea and vomiting, which are most common during dose increases.

If you miss a dose and the next scheduled dose is more than two days away, take the missed dose as soon as possible. If the next dose is less than two days away, skip the missed dose and resume your regular schedule [2]. Never take two doses within 48 hours. Store unused Wegovy pens in the refrigerator between 2°C and 8°C, and protect from light.

Managing Side Effects During Treatment

The most common side effects of Wegovy are gastrointestinal symptoms including nausea, diarrhoea, vomiting, constipation, and abdominal pain, which typically decrease over time as your body adjusts [2]. These effects are usually mild to moderate and can be managed by eating smaller meals, avoiding high-fat foods, and staying well-hydrated. If side effects persist or become severe, your prescriber may slow the dose escalation schedule or adjust your treatment plan. Serious but rare side effects include pancreatitis, gallbladder problems, and changes in vision; seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, or sudden vision changes.

Who Can Use Wegovy Injections in the UK

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [2]. The medication is intended as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management.

Wegovy is not suitable for everyone. You should not use this medication if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or a previous serious hypersensitivity reaction to semaglutide [2]. Inform your prescriber if you have a history of pancreatitis, diabetic retinopathy, kidney problems, or are pregnant, planning pregnancy, or breastfeeding.

During your free online consultation at Cured Pharmacy, our UK-registered prescribers will review your complete medical history, current medications, and weight loss goals to determine whether Wegovy is appropriate and safe for you. This clinical assessment typically takes under three minutes to complete and ensures you receive personalised treatment recommendations based on current NICE and MHRA guidance.

Starting Your Wegovy Treatment at Cured Pharmacy

Beginning your Wegovy treatment is straightforward. Complete our free online clinical assessment, which asks about your medical history, current health conditions, and weight loss goals. A UK-registered prescriber reviews your assessment, typically within hours, and approves your prescription if clinically appropriate. Apply discount code WEIGHTLOSSNEW at checkout for 10% off your first order. Your medication is dispensed by our GPhC-registered pharmacy and delivered discreetly to your door with next-day tracked shipping. Ongoing prescriptions can be managed through your online account with continued prescriber support throughout your weight loss journey.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency (MHRA). Retrieved from https://www.medicines.org.uk/emc/product/13799
3. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
4. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., Lingvay, I., & STEP 2 Study Group. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to prescribed treatment, dietary modifications, and lifestyle changes.